hrs4r
 I want to donate

DAVID CRUZ GARCIA

Firma
DAVID CRUZ-GARCIA
Position
Investigador/a Pre-doctoral – R1
Predoctoral Researchers – R1

Projectes

Codi oficial: La Marató 201906-30 Start date:30/09/2020 Data fi: 29/09/2023 Investigador/a principal: JOAQUIM BOSCH BARRERA Organisme finançador: FUNDACIO LA MARATO TV3 Ajuda: 109,562.50 €

Publicacions

0

5 '-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics

EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109, 755-764 dx.doi.org/10.1111/ejh.13862
0

Workflows and Outcomes in Patients With Suspected Large Vessel Occlusion Stroke Triaged in Urban and Nonurban Areas.

Stroke, 2022, 53, 3728-3740 dx.doi.org/10.1161/STROKEAHA.122.040768

Díaz-Santa J, Rodríguez-Romanos R, Osca G, Pratcorona M, Garrido A, Coll R, Moret C, Escoda L, Tormo M, Heras I, Arnan M, Vives S, Salamero O, Lloveras N, Bargay J, Sampol A, Cruz D, Garcia A, Quiñones T, Esteve J, Sierra J, Gallardo D, on the behalf of CETLAM Group

UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy.

Leukemia, 2020, 34, 2925-2933 dx.doi.org/10.1038/s41375-020-0784-2

Cruz D, Costa P, Sagüés M

Meningeal cryptococcosis in a patient with angioimmunoblastic lymphoma treated with alemtuzumab.

MEDICINA CLINICA, 2019, 152 dx.doi.org/10.1016/j.medcli.2018.05.030

Formulari de contacte

About IDIBGI!

menu